Colgate-Palmolive (CL) PT Lowered to $80.00

Colgate-Palmolive (NYSE:CL) had its price objective dropped by equities research analysts at Morgan Stanley from $82.00 to $80.00 in a research report issued on Friday. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 14.66% from the stock’s previous close.

Other research analysts have also issued reports about the company. Zacks Investment Research raised Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $84.00 target price on the stock in a report on Monday, January 8th. BNP Paribas lowered Colgate-Palmolive from an “outperform” rating to an “underperform” rating in a report on Tuesday, January 30th. Citigroup boosted their target price on Colgate-Palmolive from $75.00 to $80.00 and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Jefferies Group reissued a “hold” rating and set a $79.00 target price on shares of Colgate-Palmolive in a report on Friday, January 26th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $75.00 target price on shares of Colgate-Palmolive in a report on Wednesday. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. Colgate-Palmolive has an average rating of “Hold” and a consensus target price of $77.69.

NYSE:CL opened at $69.77 on Friday. The company has a market cap of $63,093.55, a price-to-earnings ratio of 24.31, a P/E/G ratio of 2.72 and a beta of 0.74. Colgate-Palmolive has a twelve month low of $67.86 and a twelve month high of $77.91. The company has a current ratio of 1.36, a quick ratio of 1.00 and a debt-to-equity ratio of 27.02.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Friday, January 26th. The company reported $0.75 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.75. The firm had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.92 billion. Colgate-Palmolive had a return on equity of 1,716.69% and a net margin of 13.10%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 EPS. research analysts forecast that Colgate-Palmolive will post 3.18 EPS for the current fiscal year.

In related news, CTO Patricia Verduin sold 1,572 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $70.17, for a total value of $110,307.24. Following the completion of the sale, the chief technology officer now directly owns 50,675 shares in the company, valued at approximately $3,555,864.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Noel R. Wallace sold 126,304 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $73.78, for a total value of $9,318,709.12. Following the completion of the sale, the chief operating officer now owns 305,631 shares of the company’s stock, valued at $22,549,455.18. The disclosure for this sale can be found here. Insiders sold a total of 474,305 shares of company stock valued at $33,776,113 over the last 90 days. 1.02% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. lifted its position in shares of Colgate-Palmolive by 15.7% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 81,249 shares of the company’s stock valued at $6,130,000 after acquiring an additional 11,036 shares during the period. Certified Advisory Corp bought a new stake in shares of Colgate-Palmolive during the 4th quarter valued at $143,000. Ackerman Capital Advisors LLC bought a new stake in shares of Colgate-Palmolive during the 4th quarter valued at $368,000. Colonial Trust Advisors lifted its position in shares of Colgate-Palmolive by 22.5% during the 4th quarter. Colonial Trust Advisors now owns 16,653 shares of the company’s stock valued at $1,256,000 after acquiring an additional 3,062 shares during the period. Finally, Cedar Hill Associates LLC bought a new stake in shares of Colgate-Palmolive during the 4th quarter valued at $203,000. Institutional investors and hedge funds own 73.64% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Colgate-Palmolive (CL) PT Lowered to $80.00” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3373498/colgate-palmolive-cl-pt-lowered-to-80-00.html.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

Analyst Recommendations for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Anticipate Finish Line, Inc.  Will Post Quarterly Sales of $422.09 Million
Brokerages Anticipate Finish Line, Inc. Will Post Quarterly Sales of $422.09 Million
MediBloc Price Up 8.3% This Week
MediBloc Price Up 8.3% This Week
Factom Market Capitalization Achieves $143.79 Million
Factom Market Capitalization Achieves $143.79 Million
Reviewing Genomic Health  and CareDx
Reviewing Genomic Health and CareDx
Financial Contrast: Valero Energy  and Vertex Energy
Financial Contrast: Valero Energy and Vertex Energy
Comparing Verint Systems  and VASCO Data Security International
Comparing Verint Systems and VASCO Data Security International


© 2006-2018 Ticker Report. Google+.